YD-3 | CAS#170632-41-4 | PAR4 antagonist

MedKoo Cat#: 126666 | Name: YD-3

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YD-3 is a PAR4 antagonist. YD-3 inhibited the aggregation of washed rabbit platelets caused by thrombin (IC(50)=28.3 microM),. YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. YD-3 inhibits thrombin-induced VSMC growth via the Ras- and ERK1/2-mediated signaling pathway. YD-3 predominantly inhibited thrombin-induced vascular endothelial growth factor receptor 2 (Flk-1) expression, but not extracellular signal-regulated kinase 1/2 phosphorylation, using Western blot analysis. YD-3 may have benefit in elucidating pathophysiology induced by thrombin-induced angiogenesis.

Chemical Structure

YD-3

CAS#170632-41-4

Theoretical Analysis

MedKoo Cat#: 126666

Name: YD-3

CAS#: 170632-41-4

Chemical Formula: C23H20N2O2

Exact Mass: 356.1525

Molecular Weight: 356.43

Elemental Analysis: C, 77.51; H, 5.66; N, 7.86; O, 8.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

YD-3; YD3; YD 3

IUPAC/Chemical Name

ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate

InChi Key

LPROLPQTWKDPNU-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H20N2O2/c1-2-27-23(26)19-14-12-18(13-15-19)22-20-10-6-7-11-21(20)25(24-22)16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3

SMILES Code

CCOC(=O)C1=CC=C(C=C1)C2=NN(C3=CC=CC=C32)CC4=CC=CC=C4

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Angiogenesis is a process that involves endothelial cell proliferation, migration, invasion, and tube formation, and the inhibition of these processes has implications for angiogenesis-mediated disorders.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 356.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhang Z, Shi W, Gu J, Song S, Xiao M, Yao J, Liu Y, Jiang J, Miao M. Short day promotes gall swelling by a CONSTANS-FLOWERING LOCUS T pathway in Zizania latifolia. Plant J. 2024 Nov;120(3):1014-1031. doi: 10.1111/tpj.17033. Epub 2024 Sep 18. PMID: 39292875. 2: Arepally S, Kim T, Kim G, Yang H, Park JK. Exploring Synthetic Strategies for 1H-Indazoles and Their N-Oxides: Electrochemical Synthesis of 1H-Indazole N-Oxides and Their Divergent C-H Functionalizations. Angew Chem Int Ed Engl. 2023 Jun 26;62(26):e202303460. doi: 10.1002/anie.202303460. Epub 2023 May 12. PMID: 37086084. 3: Moschonas IC, Kellici TF, Mavromoustakos T, Stathopoulos P, Tsikaris V, Magafa V, Tzakos AG, Tselepis AD. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand. Platelets. 2017 Dec;28(8):812-821. doi: 10.1080/09537104.2017.1282607. Epub 2017 Mar 7. PMID: 28267389. 4: Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, Holinstat M, Shaw CA, Bray PF. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014 Nov 27;124(23):3450-8. doi: 10.1182/blood-2014-04-572479. Epub 2014 Oct 7. PMID: 25293779; PMCID: PMC4246040. 5: Hosokawa K, Ohnishi T, Miura N, Sameshima H, Koide T, Tanaka KA, Maruyama I. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thromb Res. 2014 Jan;133(1):66-72. doi: 10.1016/j.thromres.2013.10.037. Epub 2013 Oct 31. PMID: 24268424. 6: Wu CC, Wang WY, Wei CK, Teng CM. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets. Thromb Haemost. 2011 Jan;105(1):88-95. doi: 10.1160/TH10-05-0305. Epub 2010 Nov 5. PMID: 21057701. 7: Wu CC, Wu SY, Liao CY, Teng CM, Wu YC, Kuo SC. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin- induced platelet aggregation. Br J Pharmacol. 2010 Oct;161(3):643-58. doi: 10.1111/j.1476-5381.2010.00921.x. PMID: 20880402; PMCID: PMC2990161. 8: Peng CY, Pan SL, Pai HC, Tsai AC, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM. The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo. Shock. 2010 Dec;34(6):580-5. doi: 10.1097/SHK.0b013e3181df00a3. PMID: 20351626. 9: Andrews JM, Fraser RJ, Heddle R, Hebbard G, Checklin H. Is esophageal dysphagia in the extreme elderly (>or=80 years) different to dysphagia younger adults? A clinical motility service audit. Dis Esophagus. 2008;21(7):656-9. doi: 10.1111/j.1442-2050.2008.00823.x. Epub 2008 May 2. PMID: 18459995. 10: Chen HS, Kuo SC, Teng CM, Lee FY, Wang JP, Lee YC, Kuo CW, Huang CC, Wu CC, Huang LJ. Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg Med Chem. 2008 Feb 1;16(3):1262-78. doi: 10.1016/j.bmc.2007.10.070. Epub 2007 Oct 25. PMID: 17988878. 11: Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol. 2006 Sep 28;546(1-3):142-7. doi: 10.1016/j.ejphar.2006.07.004. Epub 2006 Jul 14. PMID: 16890935. 12: Huang LJ, Shih ML, Chen HS, Pan SL, Teng CM, Lee FY, Kuo SC. Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-angiogenic agents. Bioorg Med Chem. 2006 Jan 15;14(2):528-36. doi: 10.1016/j.bmc.2005.08.032. Epub 2005 Oct 3. PMID: 16202611. 13: Peng CY, Pan SL, Guh JH, Liu YN, Chang YL, Kuo SC, Lee FY, Teng CM. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost. 2004 Dec;92(6):1232-9. doi: 10.1160/TH04-04-0216. PMID: 15583728. 14: Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Teng CM. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost. 2003 Aug;90(2):299-308. doi: 10.1160/TH03-02-0103. PMID: 12888878. 15: Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Lee CY, Teng CM. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost. 2002 Jun;87(6):1026-33. PMID: 12083482. 16: Rode M, Borgschulte A, Jacob A, Stellmach C, Barkow U, Schoenes J. Evidence for Ionic Bonding in YH(3-delta). Phys Rev Lett. 2001 Dec 3;87(23):235502. doi: 10.1103/PhysRevLett.87.235502. Epub 2001 Nov 16. PMID: 11736459. 17: Wu CC, Huang SW, Hwang TL, Kuo SC, Lee FY, Teng CM. YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol. 2000 Jul;130(6):1289-96. doi: 10.1038/sj.bjp.0703437. PMID: 10903968; PMCID: PMC1572197. 18: Negri MC, Swift NA, Carfagno D, Neff RA, North J. Selective removal of plutonium 238 from a canal sediment using a carbonate-chelant soil washing technology (ACT*DE*CON). J Hazard Mater. 1999 Apr 23;66(1-2):99-118. doi: 10.1016/s0304-3894(98)00208-8. PMID: 10379033. 19: LaFontaine TP, Londeree BR, Spath WK. The maximal steady state versus selected running events. Med Sci Sports Exerc. 1981;13(3):190-3. PMID: 7253872.